Write a 100-350 word essay about human UGT2B15: it function, reaction pathways it participates in, where it is located and diseases related to it.  Provide 3-5 key references where I can find more information.


Human UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) is an important enzyme in the body's detoxification system. As part of the UDP-glucuronosyltransferase (UGT) family, UGT2B15 is involved in the glucuronidation process, a major phase II metabolic reaction. This process involves conjugating glucuronic acid to various substances, including drugs, steroids, and other lipophilic compounds, thus increasing their solubility and facilitating their excretion.

UGT2B15 is primarily expressed in the liver, an organ central to metabolism and detoxification. However, it is also found in other tissues such as the prostate, breast, and brain. The enzyme plays a significant role in the metabolism of endogenous steroids, including androgens and estrogens, which are crucial for the regulation of reproductive and other physiological processes.

One of the notable aspects of UGT2B15 is its role in drug metabolism. It is involved in the detoxification of several important medications, including opioids like oxycodone and certain nonsteroidal anti-inflammatory drugs (NSAIDs). Genetic variations in UGT2B15 can significantly impact the metabolism of these drugs, influencing their efficacy and the risk of adverse effects. For example, certain UGT2B15 polymorphisms are associated with altered oxycodone metabolism, affecting pain management and the risk of opioid addiction.

Moreover, the role of UGT2B15 in steroid metabolism suggests its potential involvement in diseases related to hormone regulation. For instance, altered UGT2B15 activity may influence the risk and progression of hormone-sensitive cancers such as breast and prostate cancer.

For more detailed information on UGT2B15, its function, and related diseases, the following key references are recommended:

1. Green, M.D., et al. (2000). "Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 2B15." Drug Metabolism and Disposition, 28(7), 811-817.

2. Court, M.H. (2010). "Interindividual variability in hepatic drug glucuronidation: Influence of UGT enzyme polymorphisms." Clinical Pharmacokinetics, 49(9), 571-590.

3. Levesque, E., et al. (2007). "The impact of UGT2B polymorphisms on the clinical outcome of patients with metastatic breast cancer treated with tamoxifen." Pharmacogenomics Journal, 7(1), 58-64.

4. Turgeon, D., et al. (2003). "Pharmacogenomic profiling of estrogen metabolizing enzymes in the breast." Journal of Steroid Biochemistry and Molecular Biology, 86(3-5), 415-424.

5. Smith, H.S., et al. (2012). "Pain management and the role of pharmacogenomics." Pain Physician, 15(3 Suppl), ES95-ES123.

These references provide insights into the biochemical role of UGT2B15 in glucuronidation, its importance in drug metabolism and steroid hormone regulation, and the implications of its genetic variability in pharmacogenetics, pain management, and cancer risk.